| Date | Title | Description | |
|---|---|---|---|
| 12 Mar 2024 | On business and financial situation | ROVI, Insud Pharma and Innvierte (CDTI) create a company for the research and development of advanced therapies | Download |
| 08 Mar 2024 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 1 March and 7 March 2024 | Download |
| 07 Mar 2024 | On corporate transactions | ROVI notes the recent press speculation and informs about the assessment of potential strategic alternatives | Download |
| 01 Mar 2024 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 23 February and 29 February 2024 | Download |
| 27 Feb 2024 | Annual Financial Reports and Audit Reports | The Company submits the 2023 Annual Financial Report | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 31 Jan 2020 | R&D: new licenses, patents and registered trademarks | The Company informs about the commencement of the assessment process to obtain marketing authorisation for Doria® in the European Union | Download |
| 08 Jan 2020 | Liquidity contracts and specialists | Liquidity contract: transactions conducted in the fourth quarter of 2019 | Download |
| 20 Dec 2019 | Composition of the board of directors | The Company informs about the composition of its Board of Directors and its Audit and Appointments and Remuneration Committees. | Download |
| 24 Nov 2019 | Strategic plans, profit forecasts and presentations | The Company releases the presentation related to its strategy update because of the 2019 Investor Day. | Download |
| 07 Nov 2019 | Information on P&L | ROVI releases the press release related to the first nine months 2019 financial results | Download |